Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618641 · ClinicalTrials.gov registry record · Phase 2
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
A Phase 2 study, sponsored by Diwakar Davar.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03618641 is a Phase 2 study that has completed, run by Diwakar Davar. The registered enrollment target is 34 participants.
The verdict
NCT03618641, a Phase 2 study, has completed, sponsored by Diwakar Davar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
Interventions
- BIOLOGICAL Nivolumab
- DRUG CMP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03618641
The ClinicalTrials.gov registry entry for NCT03618641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03618641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03618641 about?
NCT03618641 is a clinical study titled "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease". The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
What is the current status of trial NCT03618641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-08-08. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03618641?
The interventions under investigation include: Nivolumab (BIOLOGICAL), CMP-001 (DRUG).
Who is sponsoring clinical trial NCT03618641?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.